Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioXcel Therapeutics, Inc. - Common Stock (NQ:BTAI)

1.790 UNCHANGED
Streaming Delayed Price Updated: 1:21 PM EDT, Jun 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioXcel Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Lost Money in BioXcel Therapeutics, Inc? Gibbs Law Group Investigates Potential Securities Law Violations
From Gibbs Law Group
Via Business Wire
ROSEN, A LEADING AND RANKED FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Analyst Expectations for BioXcel Therapeutics's Future
Via Benzinga
Calling All BioXcel Therapeutics, Inc. (BTAI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
3 Biotech Stocks to Sell Before They Damage Your Portfolio
With the Street generally bearish towards the biotech sector, investors need to identify biotech stocks to avoid at this point. 
Via InvestorPlace
Calling All BioXcel Therapeutics, Inc. (BTAI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)
From Law Offices of Howard G. Smith
Via Business Wire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)
From Glancy Prongay & Murray LLP
Via Business Wire
BTAI CLASS ACTION ANNOUNCEMENT:  Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against BioXcel Therapeutics, Inc. (BTAI)
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
BIOXCEL THERAPEUTICS, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against BioXcel Therapeutics, Inc. (NASDAQ: BTAI)
From Bernstein Liebhard LLP
Via GlobeNewswire
BIOXCEL SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAI
From Kahn Swick & Foti, LLC
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against BioXcel Therapeutics, Inc. (BTAI)
From Robbins LLP
Via Business Wire
BTAI INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that BioXcel Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the BioXcel Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
EQUITY ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – BTAI
From Rosen Law Firm
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of BioXcel Therapeutics, Inc. (BTAI) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
BTAI CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against BioXcel Therapeutics, Inc.
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of BioXcel Therapeutics, Inc. (BTAI) Investors
From Law Offices of Howard G. Smith
Via Business Wire
BTAI CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against BioXcel Therapeutics, Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why BioXcel Therapeutics Stock Was Bouncing Back This Week
What a difference a handful of trading days has made for the company. 
Via The Motley Fool
Levi Strauss, Riot Platforms And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded slightly lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Affirm Holdings, Applied Digital And Other Big Stocks Moving Lower On Thursday
U.S. stocks traded lower, with the Dow Jones dropping more than 450 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day off right with a breakdown of the biggest pre-market stock movers traders need to watch on Thursday! 
Via InvestorPlace
Perion Network And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
BioXcel Therapeutics Inc. (NASDAQ: BTAI) Near the Top of Equities by Percentage Gain on 7/5
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in... 
Via Benzinga
Dow Drops 150 Points; US Factory Orders Increase 0.3% In May
U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.46% to 34,259.45 while the NASDAQ fell... 
Via Benzinga
Wells Fargo To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday
Jefferies boosted the price target for ACM Research, Inc. (NASDAQ: ACMR) from $9 to $23.4. Jefferies analyst Nick Cheng upgraded the stock from Underperform to Buy. ACM Research shares fell 2.2% to... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.